The 2018 Annual Meeting of the American Society for Bone and Mineral Research ( ASBMR) featured many important reports about osteoporosis drugs. https://www.medscape.com/viewcollection/34648
An especially important one discussed rebound fractures following discontinuation of Denosumab - which is Prolia.